Pressure mounts for BP buy-back

The Investment Column

The management at British Petroleum could well have been singing Labour's campaign anthem, "Things can only get better", as they unveiled yet another set of record profits for the first quarter yesterday. Whether or not the chairman, Sir David Simon, decides to join Tony Blair's merry band, the stock market was cheering. The share price ended 29p higher at 732.5p as analysts asked the big question: whether BP will be tempted into a more ambitious exercise to return value to investors. BP's chief executive John Browne cautiously insisted share buy-backs or special dividends were not on the immediate agenda yesterday, but with numbers like these the markets are salivating.

Progress in all directions was better than expected. Replacement cost profits before taxes and exceptional items, the best underlying measure of performance, surged by 19 per cent in sterling terms to pounds 755m, while the result in dollars was up 27 per cent, the difference reflecting the surge in sterling over the past year. The return on capital climbed to 19 per cent, the kind of figure Shell's top team would die for.

Better still, BP appears to have overcome wobbles this year about falling oil prices after the excesses of 1996, when a barrel of crude was selling for as much as $25. So far in 1997 prices have dipped to $18, which BP insisted was in line with a long-term trading range of between $16 and $19. This compares with the company's internal benchmark for investment projects of an ultra cautious $14.

Against falling prices, BP has seen even faster benefits from its self- help programme, chanted like a corporate mantra from office to office in the hunt for extra profit. To recap, the target set in 1995 was to save $1.5bn over five years from cost cutting and higher productivity, yet last year alone BP saved $600m and promptly brought forward its timetable by 12 months.

In this quarter it has saved another $120m and is hoping for even more towards the end of the year, so the internal target for 1997 of $300m looks increasingly conservative. Part of the drive behind these improvements comes from naked self-interest, as BP executives get their full personal bonuses if savings reach twice the target level.

After a dividend hike in the last quarter it was too much to hope for another one this time, though further increases in the second half are now certain. There is no constraint from borrowings, which at $6bn compare with long-term aspirations of $7bn to $8bn, but the reason Mr Browne remains cagey about raising the payout is, or course, political. Dishing out cash in special dividends or buy-backs would be a red rag to Labour as the other Mr Brown (Gordon that is) contemplates raising North Sea oil tax. Yet the pressure from the market for BP to do something by the end of the year is becoming intense.

Full-year profits of pounds 2.94bn would put the shares on a forward multiple of 14. Currently yielding 3.3 per cent and with the case for special payouts all but unanswerable, the shares are a definite hold.

Shire's portfolio

is blossoming

Shire Pharmaceuticals is putting in a strong bid to be taken seriously as more than just a biotechnology hopeful. Following on from February's chunky pounds 105m acquisition of Pharmavene, a US drugs delivery group, yesterday the group was demonstrating the breadth of its drugs pipeline in a research and development update.

Galantamine, the compound originally derived from daffodils which represents Shire's lead product, is proving to have wider medical properties than originally thought. Initially indicated for use against Alzheimer's disease, the group is now ready to test its use against chronic fatigue syndrome, also known as ME or "yuppie flu". A 300-patient trial into both efficacy and tolerability will start later this month, with another involving 60 people in Iceland due to start in September. If it ever reaches doctors' surgeries, perhaps in 2005, it could be attacking a $2.5bn market for which there is no current treatment, the company believes. But there is more, for early observations using galantamine against Alzheimer's appear to show it is effective against both rheumatoid arthritis and osteoarthritis, two other big markets.

Meanwhile, analysts are excited by the prospects for Lambda, a treatment for reducing phosphate levels in the blood of people with kidney disease. Untreated, a build up of phosphate can lead to bone disease. Shire is already the market leader in the UK in this area with its calcium carbonate product, but Lambda is said to offer substantial improvements. The potential market is 1.6 million patients world-wide and this could be the first drug to be marketed outside the UK directly by Shire.

Finally, Shire reckons Nifedipine SR, a cardiovascular which could be launched before 2000, might sell into a US market worth $1.1bn. That will depend, however, on whether it can overcome expected legal action from Pfizer, the current market leader.

The wide portfolio at Shire is matched by the depth of its management. Much still depends on the outcome of the phase III tests for the Alzheimer's drug, due in September, but Lehman Brothers estimate the shares' net present value at 274p, rising to 364p next year. That is below the current market price of 219p, up 2p, and makes them a reasonable punt.

Sidlaw repackages its strategy

Sidlaw has been through the wars since its disastrous 1993 decision to step up the scale of its flexible packaging operations. That led to losses over the past two years and a plunging share price, but John Durston, who took over as chief executive in the autumn, is starting to use his experience in the industry to good effect.

Last year's move to dump the oil services business took the decision to concentrate on packaging to its logical conclusion. But Mr Durston has also put a lot of effort into improving customer service and efficiency, two areas which appeared neglected under the dash for volume policy which led Sidlaw astray before. The fruits of these labours are reflected in the group's half-year results to March, although the figures are distorted by the pounds 17.3m profit on the sale of oil services and a pounds 1.7m charge for rationalisation.

Stripping that lot out, the underlying pre-tax total rose from a loss of pounds 1.41m to a profit of pounds 1.75m.

The proceeds of the disposal of oil services cut the interest charge from pounds 2.09m to pounds 162,000 and left net cash of pounds 3.3m in March. The group reckons it has firepower for pounds 25m of acquisitions, but nothing is imminent. In the meantime, it will be pushed into borrowings again by a pounds 12m capital expenditure programme this year.

Part of the spending will help service a pounds 6m-a-year contract to supply Cadbury with wrappers and should also improve efficiency. Sidlaw also claims to have won back most of the customers lost during its difficult patch.

The problem remains, however, that the group is still highly dependent on mature or declining markets like biscuit packets and bread bags, which remain at the mercy of the supermarket price wars. Even with innovative products like its P-Plus "breathable" fresh-produce wrapper, it still has to prove it is not just running to stand still.

Profits of pounds 3.5m in the full year would put the shares, down 3p at 103.5p, on a forward p/e of 23. The shadow of previous rights issues at 275p and 180p hangs over the shares, but they are probably still worth holding.

Start your day with The Independent, sign up for daily news emails
News
i100
News
Bobbi Kristina Brown, daughter of the late singer Whitney Houston, poses at the premiere of
people
News
people
News
The frequency with which we lie and our ability to get away with it both increase to young adulthood then decline with age, possibly because of changes that occur in the brain
scienceRoger Dobson knows the true story, from Pinocchio to Pollard
Voices
The male menopause: those affected can suffer hot flushes, night sweats, joint pain, low libido, depression and an increase in body fat, among other symptoms
voicesSo the male menopause is real, they say, but what would the Victorians, 'old' at 30, think of that, asks DJ Taylor
Life and Style
health
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: DBA Developer - SQL Server

£30000 - £35000 per annum: Recruitment Genius: This is an exciting opportunity...

Recruitment Genius: Customer Service Administrator

£13000 - £15000 per annum: Recruitment Genius: Are you passionate about custom...

Recruitment Genius: Dialler Administrator

£22000 - £25000 per annum: Recruitment Genius: Main purpose: Under the directi...

Ashdown Group: Contracts Manager - City of London

£35000 - £37000 per annum + benefits : Ashdown Group: Contracts Manager - City...

Day In a Page

Turkey-Kurdish conflict: Obama's deal with Ankara is a betrayal of Syrian Kurds and may not even weaken Isis

US betrayal of old ally brings limited reward

Since the accord, the Turks have only waged war on Kurds while no US bomber has used Incirlik airbase, says Patrick Cockburn
VIPs gather for opening of second Suez Canal - but doubts linger over security

'A gift from Egypt to the rest of the world'

VIPs gather for opening of second Suez Canal - but is it really needed?
Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

Fashion editor, Alexander Fury, applauds a man who clearly has more important things on his mind
The male menopause and intimations of mortality

Aches, pains and an inkling of mortality

So the male menopause is real, they say, but what would the Victorians, 'old' at 30, think of that, asks DJ Taylor
Man Booker Prize 2015: Anna Smaill - How can I possibly be on the list with these writers I have idolised?

'How can I possibly be on the list with these writers I have idolised?'

Man Booker Prize nominee Anna Smaill on the rise of Kiwi lit
Bettany Hughes interview: The historian on how Socrates would have solved Greece's problems

Bettany Hughes interview

The historian on how Socrates would have solved Greece's problems
Art of the state: Pyongyang propaganda posters to be exhibited in China

Art of the state

Pyongyang propaganda posters to be exhibited in China
Mildreds and Vanilla Black have given vegetarian food a makeover in new cookbooks

Vegetarian food gets a makeover

Long-time vegetarian Holly Williams tries to recreate some of the inventive recipes in Mildreds and Vanilla Black's new cookbooks
The haunting of Shirley Jackson: Was the gothic author's life really as bleak as her fiction?

The haunting of Shirley Jackson

Was the gothic author's life really as bleak as her fiction?
Bill Granger recipes: Heading off on holiday? Try out our chef's seaside-inspired dishes...

Bill Granger's seaside-inspired recipes

These dishes are so easy to make, our chef is almost embarrassed to call them recipes
Ashes 2015: Tourists are limp, leaderless and distinctly UnAustralian

Tourists are limp, leaderless and distinctly UnAustralian

A woefully out-of-form Michael Clarke embodies his team's fragile Ashes campaign, says Michael Calvin
Blairites be warned, this could be the moment Labour turns into Syriza

Andrew Grice: Inside Westminster

Blairites be warned, this could be the moment Labour turns into Syriza
HMS Victory: The mystery of Britain's worst naval disaster is finally solved - 271 years later

The mystery of Britain's worst naval disaster is finally solved - 271 years later

Exclusive: David Keys reveals the research that finally explains why HMS Victory went down with the loss of 1,100 lives
Survivors of the Nagasaki atomic bomb attack: Japan must not abandon its post-war pacifism

'I saw people so injured you couldn't tell if they were dead or alive'

Nagasaki survivors on why Japan must not abandon its post-war pacifism
Jon Stewart: The voice of Democrats who felt Obama had failed to deliver on his 'Yes We Can' slogan, and the voter he tried hardest to keep onside

The voter Obama tried hardest to keep onside

Outgoing The Daily Show host, Jon Stewart, became the voice of Democrats who felt the President had failed to deliver on his ‘Yes We Can’ slogan. Tim Walker charts the ups and downs of their 10-year relationship on screen